Log In Get Started
Stock Markets July 28, 2026 02:29 AM

Novacyt Posts 18% H1 Revenue Gain as Instrument Sales and Acquisitions Lift Results

LightBench Discover adoption and Southern Cross Diagnostics deal underpin growth while cost-savings plan and pending IVDR accreditation remain focal points

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn

Novacyt reported first-half 2026 revenue of

Novacyt Posts 18% H1 Revenue Gain as Instrument Sales and Acquisitions Lift Results
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Novacyt reported first-half 2026 revenue of , an 18% increase year-on-year.
  • Instrumentation revenue grew roughly 30% year-on-year as the LightBench Discover platform gained market adoption, while the clinical division expanded by more than 20%, helped by non-invasive prenatal testing and sickle cell product sales.
  • Southern Cross Diagnostics, acquired in March, added to revenue in the period after the acquisition.

Novacyt, the France-headquartered molecular diagnostics company, reported revenue of

Note: The publisher has limited the article content for display purposes.

Novacyt posted revenue of

Financial results and segment drivers

For the first half of 2026 Novacyt recorded total revenue of

Detailed segment performance was as follows:

  • Instrumentation: Approximately 30% year-on-year growth, attributed to market uptake of the LightBench Discover platform.
  • Clinical: More than 20% year-on-year growth, supported by demand for non-invasive prenatal testing technology and sales of sickle cell disease products.

Acquisition contribution

Southern Cross Diagnostics, which Novacyt acquired in March, added

The business contributed

Regional trends

Novacyt reported regional increases with revenue from the Americas rising by more than 30% and the Asia-Pacific region increasing by about 22%. Both regions saw demand driven by instrument sales and reproductive health products.

Cost programme and regulatory outlook

The company is implementing a restructuring programme designed to deliver up to in annualised cost savings.

Separately, Novacyt expects to receive IVDR accreditation for its DPYD kit in the coming months.

Risks

  • IVDR accreditation for the DPYD kit is expected in the coming months, leaving regulatory approval uncertain until that accreditation is received - impacting regulatory-sensitive product launches and clinical diagnostics revenue.
  • The restructuring programme is projected to deliver up to in annualised savings, which indicates potential variability in the ultimate cost reductions achieved - affecting profitability in the healthcare and diagnostics segments.
  • Revenue contribution from Southern Cross Diagnostics applies only to the period following its March acquisition, which limits comparability with full-period organic performance and could affect interpretation of growth drivers in the medical diagnostics market.

More from Stock Markets

LVMH Stock Dips as Fashion Division's Modest Recovery Fails to Fully Comfort Investors Jul 28, 2026 Tokyo shares retreat; Nikkei 225 posts 3.83% decline to one-month low Jul 28, 2026 Philips Says U.S. Order Delays and China Market Pressure Weighed on Q2 Results Jul 28, 2026 Everplay Sticks to FY26 Targets as First-Half Trading Supports Outlook Jul 28, 2026 Luceco Lifts FY27 and FY28 EBITA Guidance After Robust H1 2026 Performance Jul 28, 2026